PMID- 34860610
OWN - NLM
STAT- MEDLINE
DCOM- 20220428
LR  - 20220531
IS  - 1205-7541 (Electronic)
IS  - 0008-4212 (Linking)
VI  - 100
IP  - 5
DP  - 2022 May
TI  - beta-elemene relieves neuropathic pain in mice through the regulation on C-X-C motif 
      chemokine receptor 3 and GABAA receptor.
PG  - 422-431
LID - 10.1139/cjpp-2021-0636 [doi]
AB  - beta-elemene (Bel) is a sesquiterpene compound that has shown potential in the 
      antinociceptive treatment. This study focused on the function of Bel in 
      neuropathic pain relief in mice. A murine model with spared nerve injury (SNI) 
      was established and treated with Bel. The paw withdrawal thresholds in response 
      to mechanical and thermal stimulations were examined using von Frey filaments. 
      The L4-L6 spinal dorsal horn tissue samples were collected for histological 
      examination. Bel treatment reduced the sensitivities of model mice to mechanical 
      and thermal stimulations, and it inhibited activation of microglia and the 
      secretion of inflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha), 
      interleukin-1beta (IL-1beta), and IL-6 in tissues. Bel treatment reduced the expression 
      of nociceptor excitatory N-methyl-D-aspartate receptor (NMDAR), whereas it 
      enhanced the expression of nociceptor inhibitory gamma-aminobutyric acid A 
      (GABAA) receptor to relieve the nociception of mice. The C-X-C motif chemokine 
      receptor 3 (CXCR3) is a downstream molecule mediated by Bel. Either 
      overexpression of CXCR3 or downregulation of GABAA receptor in the tissues 
      aggravated the neuropathic pain in SNI mice which was initially relieved by Bel. 
      In conclusion, this study suggested that Bel might serve as a drug for 
      nociception management by inhibiting CXCR3 and upregulating GABAA receptor. This 
      study may offer novel insights into the field of neuropathic pain relief.
FAU - Dai, Yi
AU  - Dai Y
AD  - Department of pain, the First People's Hospital of Jiashan, Jiaxing 314100, 
      Zhejiang, P.R. China.
AD  - Department of pain, the First People's Hospital of Jiashan, Jiaxing 314100, 
      Zhejiang, P.R. China.
FAU - Zeng, Zhenhua
AU  - Zeng Z
AD  - Department of pain, the First People's Hospital of Jiashan, Jiaxing 314100, 
      Zhejiang, P.R. China.
AD  - Department of pain, the First People's Hospital of Jiashan, Jiaxing 314100, 
      Zhejiang, P.R. China.
FAU - Deng, Shuo
AU  - Deng S
AD  - Department of pain, the First People's Hospital of Jiashan, Jiaxing 314100, 
      Zhejiang, P.R. China.
AD  - Department of pain, the First People's Hospital of Jiashan, Jiaxing 314100, 
      Zhejiang, P.R. China.
FAU - Zou, Sanbao
AU  - Zou S
AD  - Department of pain, the First People's Hospital of Jiashan, Jiaxing 314100, 
      Zhejiang, P.R. China.
AD  - Department of pain, the First People's Hospital of Jiashan, Jiaxing 314100, 
      Zhejiang, P.R. China.
FAU - Dou, Tingyang
AU  - Dou T
AD  - Department of pain, the First People's Hospital of Jiashan, Jiaxing 314100, 
      Zhejiang, P.R. China.
AD  - Department of pain, the First People's Hospital of Jiashan, Jiaxing 314100, 
      Zhejiang, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20211203
PL  - Canada
TA  - Can J Physiol Pharmacol
JT  - Canadian journal of physiology and pharmacology
JID - 0372712
RN  - 0 (Cxcr3 protein, mouse)
RN  - 0 (Receptors, CXCR3)
RN  - 0 (Receptors, GABA-A)
RN  - 0 (Sesquiterpenes)
RN  - 0 (beta-elemene)
SB  - IM
MH  - Animals
MH  - Hyperalgesia/drug therapy/metabolism
MH  - Mice
MH  - *Neuralgia/drug therapy/metabolism
MH  - *Receptors, CXCR3
MH  - *Receptors, GABA-A/metabolism
MH  - *Sesquiterpenes/pharmacology/therapeutic use
MH  - Spinal Cord/metabolism
OTO - NOTNLM
OT  - CXCR3
OT  - GABAA receptor
OT  - nerf epargne
OT  - neuropathic pain relief
OT  - recepteurs GABAA
OT  - soulagement de la douleur neuropathique
OT  - spared nerve injury
OT  - beta-elemene
OT  - beta-elemene
EDAT- 2021/12/04 06:00
MHDA- 2022/04/29 06:00
CRDT- 2021/12/03 17:18
PHST- 2021/12/04 06:00 [pubmed]
PHST- 2022/04/29 06:00 [medline]
PHST- 2021/12/03 17:18 [entrez]
AID - 10.1139/cjpp-2021-0636 [doi]
PST - ppublish
SO  - Can J Physiol Pharmacol. 2022 May;100(5):422-431. doi: 10.1139/cjpp-2021-0636. 
      Epub 2021 Dec 3.